文献速递消化道肿瘤放疗放疗物理与技术

胰腺癌立体定向体部放疗剂量递增的Ⅰ期试验

Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-02-08

这项Ⅰ期剂量递增试验纳入30例胰腺癌患者,采用时间-事件持续再评估法设计,给予5次分割的40、45或50 Gy立体定向体部放疗(SBRT)。主要终点为毒性,7例(23%)出现≤2级急性毒性,2例(6.7%)出现4-5级晚期毒性且均位于45 Gy组;中位生存期自诊断起17.1个月,1年局部进展累积发生率14.2%。结论认为局部控制和生存良好,但存在不可忽视的严重晚期胃肠道毒性。

要点

  • 30例胰腺癌患者接受5次分割SBRT,剂量为40、45或50 Gy。
  • 2例(6.7%)出现4-5级晚期毒性,均发生在45 Gy组。
  • 1年局部进展累积发生率为14.2%(95%CI 4.2%-30%)。

核心结论

  • 高剂量5次分割SBRT总体显示良好的局部控制和生存,但与不可忽视的严重晚期胃肠道毒性相关。
  • 需要进一步前瞻性研究明确高剂量SBRT在胰腺癌患者中的安全性和疗效。

研究设计与样本

  • Ⅰ期剂量递增试验,采用时间-事件持续再评估法(time-to-event continual reassessment method)确定剂量。
  • 纳入30例胰腺癌患者,接受5次分割的40、45或50 Gy SBRT。
  • 允许SBRT前后进行全身治疗,但研究方案未强制要求。
  • 主要终点为毒性,任何可能归因于SBRT的≥3级急性或晚期毒性视为剂量限制性毒性。

主要发现

  • 中位随访自SBRT起为8.9个月(范围1.7-62.6个月)。
  • 3例(10%)接受40 Gy,16例(53%)接受45 Gy,11例(37%)接受50 Gy。
  • 7例(23%)出现≤2级急性毒性,2例(6.7%)出现4-5级晚期毒性且均发生在45 Gy组。
  • 中位生存期自诊断起为17.1个月,自SBRT起为9.8个月;1年局部进展累积发生率为14.2%(95%CI 4.2%-30%)。

关键数值与推荐

  • 剂量限制性毒性定义为任何可能归因于SBRT的≥3级急性或晚期毒性。
  • 剂量水平为5次分割40 Gy、45 Gy或50 Gy。

临床怎么用

  • 高剂量5次分割SBRT可用于胰腺癌并显示良好局部控制,但需警惕严重晚期胃肠道毒性。
  • 45 Gy组出现4-5级晚期毒性,临床实施该剂量时需密切监测晚期毒性。

局限性

  • 样本量小(30例),随访时间有限(中位8.9个月)。
  • 全身治疗允许但未强制,可能影响毒性及疗效评估。
  • 作者指出需进一步前瞻性研究明确安全性和疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Stereotactic body radiation therapy (SBRT) has demonstrated encouraging local tumor control rates in the treatment of pancreatic cancer, yet we lack prospective clinical trials evaluating dose-escalation strategies among patients treated with 5-fraction SBRT. This phase 1 dose-escalation trial was conducted to determine the maximum tolerated dose of SBRT in patients with pancreatic cancer. METHODS AND MATERIALS: Thirty patients with pancreatic cancer were enrolled and treated with 40, 45, or 50 Gy SBRT in 5 fractions with doses determined using a time-to-event continual reassessment method trial design. Systemic therapy was permitted before and after SBRT, but not mandated by the study protocol. Toxicity was the primary study endpoint, and any grade ≥3 acute or late toxicity potentially attributable to SBRT was considered a dose-limiting toxicity. Secondary endpoints included local progression, distant progression, and overall survival. RESULTS: The median follow up from SBRT was 8.9 months (range, 1.7-62.6 months). Nineteen patients (63%) had locally advanced disease, 3 patients (10%) had metastatic disease, and 8 patients (27%) had medically unresectable disease. Three patients (10%) received 40 Gy, 16 patients (53%) received 45 Gy, and 11 patients (37%) received 50 Gy. Seven patients (23%) experienced grade ≤2 acute toxicity, and 2 patients (6.7%) experienced grade 4 to 5 late toxicity, both of which occurred in the 45 Gy group. Median survival time was 17.1 months from the time of diagnosis and 9.8 months from SBRT. The 1-year cumulative incidence of local progression was 14.2% (95% confidence interval, 4.2%-30%). CONCLUSIONS: This dose-escalation trial evaluated high-dose SBRT delivered in 5 fractions, and overall demonstrated favorable local control and survival, but was associated with nontrivial rates of severe late gastrointestinal toxicity potentially attributable to radiation. Further prospective studies are needed to define the safety and efficacy of high-dose SBRT in patients with pancreatic cancer.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Courtney PT, Paravati AJ, Atwood TF, et al. Phase I Trial of Stereotactic Body Radiation Therapy Dose Escalation in Pancreatic Cancer. Int J Radiat Oncol Biol Phys. 2021. PMID: 33571625. doi:10.1016/j.ijrobp.2021.02.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。